| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2019 | ELAN Elanco Animal Health Inc | Urbanek David Alan | See Remarks | Buy | 228 | $26.26 | $5,986.15 | New | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Heggie Theresa | Director | Buy | 5,000 | $1.45 | $7,250.00 | +299.0% | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Barnes Alane P70 | Senior VP, Chief Legal Officer | Buy | 20,000 | $1.45 | $29,000.00 | +24.4% | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Babu Yarlagadda S66 | Senior VP - Drug Discovery | Buy | 25,000 | $1.45 | $36,250.00 | +19.1% | |
| Nov 18, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 10,598 | $114.00 | $1,208,172.00 | - | |
| Nov 18, 2019 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 11,425 | $118.86 | $1,357,975.50 | -49.9% | |
| Nov 18, 2019 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 1,000 | $54.31 | $54,314.00 | -5.4% | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Hutson Nancy J58 | Director | Buy | 10,000 | $1.45 | $14,500.00 | +23.2% | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Aselage Steve80 | Director | Buy | 15,000 | $1.45 | $21,750.00 | +224.8% | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Sniecinski Megan | Chief Business Officer | Buy | 45,000 | $1.45 | $65,250.00 | New | |
| Nov 18, 2019 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 5,000 | $115.98 | $579,900.00 | -4.4% | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Lee Kenneth B Jr | Director | Buy | 5,000 | $1.45 | $7,250.00 | +48.8% | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Stonehouse Jon P80 | President &CEO | Buy | 50,000 | $1.45 | $72,500.00 | +6.9% | |
| Nov 18, 2019 | AVDL Avadel Pharmaceuticals Plc | Glass Geoffrey Michael70 | Director | Buy | 20,000 | $4.99 | $99,800.00 | +32.9% | |
| Nov 15, 2019 | AVDL Avadel Pharmaceuticals Plc | Divis Greg J71 | Chief Executive Officer | Buy | 19,000 | $5.13 | $97,470.00 | +28.3% | |
| Nov 15, 2019 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 70,000 | $42.81 | $2,996,700.00 | -32.8% | |
| Nov 15, 2019 | AVDL Avadel Pharmaceuticals Plc | Ende Eric J81 | Director | Buy | 10,000 | $4.98 | $49,762.00 | +35.8% | |
| Nov 14, 2019 | ZTS Zoetis Inc. | Lewis Clinton A. Jr.46 | Executive Vice President | Sell | 6,123 | $116.13 | $711,063.99 | -16.7% | |
| Nov 14, 2019 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | SVP And General Counsel | Sell | 7,500 | $20.79 | $155,925.00 | -5.7% | |
| Nov 14, 2019 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 100,000 | $19.50 | $1,950,000.00 | -12.2% | |
| Nov 13, 2019 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 20,000 | $19.70 | $394,056.00 | -9.8% | |
| Nov 12, 2019 | AMRN Amarin Corp Plc\uk | Ekman Lars73 | Director | Sell | 38,600 | $19.35 | $746,759.46 | -100% | |
| Nov 12, 2019 | ZTS Zoetis Inc. | Peck Kristin C66 | Executive Vice President | Sell | 11,500 | $117.16 | $1,347,389.60 | -14.6% | |
| Nov 12, 2019 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Buy | 250,000 | $12.00 | $3,000,000.00 | +7.6% | |
| Nov 12, 2019 | TLPH Talphera, Inc. | Edwards Mark G | Director | Buy | 25,000 | $1.78 | $44,575.00 | +11.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.